Loading…
In Vitro Activity of LYS228, a Novel Monobactam Antibiotic, against Multidrug-Resistant Enterobacteriaceae
LYS228 is a novel monobactam with potent activity against LYS228 is stable to metallo-β-lactamases (MBLs) and serine carbapenemases, including carbapenemases (KPCs), resulting in potency against the majority of extended-spectrum β-lactamase (ESBL)-producing and carbapenem-resistant strains tested. O...
Saved in:
Published in: | Antimicrobial agents and chemotherapy 2018-10, Vol.62 (10) |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | LYS228 is a novel monobactam with potent activity against
LYS228 is stable to metallo-β-lactamases (MBLs) and serine carbapenemases, including
carbapenemases (KPCs), resulting in potency against the majority of extended-spectrum β-lactamase (ESBL)-producing and carbapenem-resistant
strains tested. Overall, LYS228 demonstrated potent activity against 271
strains, including multidrug-resistant isolates. Based on MIC
values, LYS228 (MIC
, 1 μg/ml) was ≥32-fold more active against those strains than were aztreonam, ceftazidime, ceftazidime-avibactam, cefepime, and meropenem. The tigecycline MIC
was 4 μg/ml against the strains tested. Against
isolates expressing ESBLs (
= 37) or displaying carbapenem resistance (
= 77), LYS228 had MIC
values of 1 and 4 μg/ml, respectively. LYS228 exhibited potent bactericidal activity, as indicated by low minimal bactericidal concentration (MBC) to MIC ratios (MBC/MIC ratios of ≤4) against 97.4% of the
strains tested (264/271 strains). In time-kill studies, LYS228 consistently achieved reductions in CFU per milliliter of 3 log
units (≥99.9% killing) at concentrations ≥4× MIC for
and
reference strains, as well as isolates encoding TEM-1, SHV-1, CTX-M-14, CTX-M-15, KPC-2, KPC-3, and NDM-1 β-lactamases. |
---|---|
ISSN: | 0066-4804 1098-6596 |
DOI: | 10.1128/AAC.00552-18 |